Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP) - PubMed

Review

Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP)

J E Kaufmann et al. J Thromb Haemost. 2003 Apr.

Free article

Abstract

The synthetic analog of vasopressin desmopressin (DDAVP) is widely used for the treatment of patients with von Willebrand disease (VWD), hemophilia A, several platelet disorders, and uremic bleeding. DDAVP induces an increase in plasma levels of von Willebrand factor (VWF), coagulation factor VIII (FVIII), and tissue plasminogen activator (t-PA). It also has a vasodilatory action. In spite of its extensive clinical use, its cellular mechanism of action remains incompletely understood. Its effect on VWF and t-PA as well as its vasodilatory effect are likely explained by a direct action on the endothelium, via activation of endothelial vasopressin V2R receptor and cAMP-mediated signaling. This leads to exocytosis from Weibel Palade bodies where both VWF and t-PA are stored, as well as to nitric oxide (NO) production via activation of endothelial NO synthase. The mechanism of action of DDAVP on FVIII plasma levels remains to be elucidated. The hemostatic effect of DDAVP likely involves additional cellular effects that remain to be discovered.

Similar articles

• Desmopressin (dDAVP): a powerful general hemostatic agent?

  Drouet L, Scrobohaci ML, Boudaoud S, Vilain G. Drouet L, et al. Nouv Rev Fr Hematol (1978). 1989;31(2):163-5. Nouv Rev Fr Hematol (1978). 1989. PMID: 2528120 Review. No abstract available.

• Comparative response of plasma VWF in dogs to up-regulation of VWF mRNA by interleukin-11 versus Weibel-Palade body release by desmopressin (DDAVP).

  Olsen EH, McCain AS, Merricks EP, Fischer TH, Dillon IM, Raymer RA, Bellinger DA, Fahs SA, Montgomery RR, Keith JC Jr, Schaub RG, Nichols TC. Olsen EH, et al. Blood. 2003 Jul 15;102(2):436-41. doi: 10.1182/blood-2003-01-0290. Epub 2003 Mar 20. Blood. 2003. PMID: 12649145

• Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP.

  Kaufmann JE, Oksche A, Wollheim CB, Günther G, Rosenthal W, Vischer UM. Kaufmann JE, et al. J Clin Invest. 2000 Jul;106(1):107-16. doi: 10.1172/JCI9516. J Clin Invest. 2000. PMID: 10880054 Free PMC article.

• Desmopressin (DDAVP) and hemostasis.

  Lethagen S. Lethagen S. Ann Hematol. 1994 Oct;69(4):173-80. doi: 10.1007/BF02215950. Ann Hematol. 1994. PMID: 7948303 Review.

Cited by

• Desmopressin treatment combined with clotting factor VIII concentrates in patients with non-severe haemophilia A: protocol for a multicentre single-armed trial, the DAVID study.

  Schütte LM, Cnossen MH, van Hest RM, Driessens MHE, Fijnvandraat K, Polinder S, Beckers EAM, Coppens M, Eikenboom J, Laros-van Gorkom BAP, Meijer K, Nieuwenhuizen L, Mauser-Bunschoten EP, Leebeek FWG, Mathôt RAA, Kruip MJHA. Schütte LM, et al. BMJ Open. 2019 Apr 23;9(4):e022719. doi: 10.1136/bmjopen-2018-022719. BMJ Open. 2019. PMID: 31015264 Free PMC article.

• Arginine vasopressin receptor 2 activation promotes microvascular permeability in sepsis.

  Lopez E, Fukuda S, Modis K, Fujiwara O, Enkhtaivan B, Trujillo-Abarca R, Ihara K, Lima-Lopez F, Perez-Bello D, Szabo C, Prough DS, Enkhbaatar P. Lopez E, et al. Pharmacol Res. 2021 Jan;163:105272. doi: 10.1016/j.phrs.2020.105272. Epub 2020 Nov 4. Pharmacol Res. 2021. PMID: 33160069 Free PMC article.

• Platelet transfusion for patients with platelet dysfunction: effectiveness, mechanisms, and unanswered questions.

  Lee RH, Kasthuri RS, Bergmeier W. Lee RH, et al. Curr Opin Hematol. 2020 Nov;27(6):378-385. doi: 10.1097/MOH.0000000000000608. Curr Opin Hematol. 2020. PMID: 32868672 Free PMC article. Review.

• Desmopressin testing in von Willebrand disease: Lowering the burden.

  Heijdra JM, Atiq F, Al Arashi W, Kieboom Q, Wuijster E, Meijer K, Kruip MJHA, Leebeek FWG, Cnossen MH; OPTI‐CLOT Study Group. Heijdra JM, et al. Res Pract Thromb Haemost. 2022 Sep 26;6(6):e12784. doi: 10.1002/rth2.12784. eCollection 2022 Aug. Res Pract Thromb Haemost. 2022. PMID: 36186107 Free PMC article.

• Low COAT platelets are frequent in patients with bleeding disorders of unknown cause (BDUC) and can be enhanced by DDAVP.

  Segot A, Adler M, Aliotta A, Matthey-Guirao E, Nagler M, Bertaggia Calderara D, Grandoni F, Gomez FJ, Alberio L. Segot A, et al. J Thromb Haemost. 2022 May;20(5):1271-1274. doi: 10.1111/jth.15687. Epub 2022 Mar 13. J Thromb Haemost. 2022. PMID: 35243754 Free PMC article. No abstract available.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science
  • Wiley

• Other Literature Sources

  • The Lens - Patent Citations Database

• Miscellaneous

  • NCI CPTAC Assay Portal